Calcijex and Zemplar drug interactions - a phase IV clinical study of FDA data


Drug interactions are reported among 42 people who take Calcijex and Zemplar. Common interactions include skin fibrosis among females, and cardiac failure among males.

The phase IV clinical study analyzes what interactions people who take Calcijex and Zemplar have. It is created by eHealthMe based on reports from the FDA, and is updated regularly. You may use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 700+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Sep, 26, 2023

42 people who take Calcijex and Zemplar together, and have interactions are studied.

What is Calcijex?

Calcijex has active ingredients of calcitriol. Currently, eHealthMe is studying from 250 Calcijex users.

What is Zemplar?

Zemplar has active ingredients of paricalcitol. It is used in kidney disease. Currently, eHealthMe is studying from 15,366 Zemplar users.

Number of Calcijex and Zemplar reports submitted per year:

Calcijex and Zemplar drug interactions.

Common Calcijex and Zemplar drug interactions by gender *:


  1. Skin fibrosis
  2. Skin hyperpigmentation
  3. Skin hypertrophy
  4. Skin induration
  5. Skin plaque
  6. Skin tightness
  7. Rash
  8. Oedema peripheral
  9. Cellulitis
  10. Deformity


  1. Cardiac failure
  2. Acute psychosis
  3. Erythema
  4. Left ventricular failure
  5. Pain
  6. Peripheral vascular disorder
  7. Tachycardia
  8. Torsade de pointes
  9. Ventricular fibrillation
  10. Deformity

Common Calcijex and Zemplar drug interactions by age *:












  1. Anxiety
  2. Dry skin
  3. Emotional distress
  4. Erythema
  5. Fibrosis
  6. General physical health deterioration
  7. Injury
  8. Joint range of motion decreased
  9. Mobility decreased
  10. Nephrogenic systemic fibrosis


  1. Scar
  2. Skin hypertrophy
  3. Skin induration
  4. Cellulitis
  5. Fatigue
  6. Fibrosis
  7. Pain of skin
  8. Skin exfoliation
  9. Skin fibrosis
  10. Skin hyperpigmentation


  1. Cardiac failure
  2. Acute psychosis
  3. Left ventricular failure
  4. Peripheral vascular disorder
  5. Tachycardia
  6. Torsade de pointes
  7. Ventricular fibrillation
  8. Renal failure
  9. Sepsis
  10. General physical health deterioration

Common conditions people have *:

  1. Pain: 14 people, 33.33%
  2. Stress And Anxiety: 12 people, 28.57%
  3. Nuclear Magnetic Resonance Imaging Brain: 12 people, 28.57%
  4. Nausea (feeling of having an urge to vomit): 12 people, 28.57%
  5. Itching: 12 people, 28.57%
  6. Hyperparathyroidism (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium): 12 people, 28.57%
  7. High Blood Cholesterol: 12 people, 28.57%
  8. Herpes Zoster: 12 people, 28.57%
  9. Gastritis Erosive (a break in the surface layer of the membrane lining the stomach with infection): 12 people, 28.57%
  10. Device Related Infection: 12 people, 28.57%

* Approximation only. Some reports may have incomplete information.

Do you take Calcijex and Zemplar?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Drug side effects by duration, gender and age:

Browse interactions between Calcijex and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Zemplar drug interactions:

Browse interactions between Zemplar and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on calcitriol and paricalcitol (the active ingredients of Calcijex and Zemplar, respectively), and Calcijex and Zemplar (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Calcijex and Zemplar.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 700+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: